E-viri
Recenzirano
Odprti dostop
-
Martínez-Cuadrón, David; Megías-Vericat, Juan E; Gil, Cristina; Bernal, Teresa; Tormo, Mar; Martínez-Sánchez, Pilar; Rodríguez-Medina, Carlos; Serrano, Josefina; Herrera, Pilar; Simón, José A Pérez; Sayas, María J; Bergua, Juan; Lavilla-Rubira, Esperanza; Amigo, Maria Luz; Benavente, Celina; Lorenzo, Jose L López; Pérez-Encinas, Manuel M; Vidriales, María B; Colorado, Mercedes; De Rueda, Beatriz; García-Boyero, Raimundo; Marini, Sandra; García-Suárez, Julio; López-Pavía, María; Gómez-Roncero, Maria I; Noriega, Víctor; López, Aurelio; Labrador, Jorge; Cabello, Ana; Sossa, Claudia; Algarra, Lorenzo; Stevenazzi, Mariana; Solana-Altabella, Antonio; Boluda, Blanca; Montesinos, Pau
Haematologica (Roma), 01/2024, Letnik: 109, Številka: 1Journal Article
Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval CI: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.